Evidence map›Paper›PMID 35903679›Full record

ArticleFrontiers in oncology2022

Construction and Comparison of Different Models in Detecting Prostate Cancer and Clinically Significant Prostate Cancer.

Yongheng Zhou, Wenqiang Qi, Jianfeng Cui, Minglei Zhong, Guangda Lv, Sifeng Qu, Shouzhen Chen, Rongyang Li, Benkang Shi, Yaofeng Zhu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yongheng ZhouDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Wenqiang QiDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Jianfeng CuiDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Minglei ZhongDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Guangda LvDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Sifeng QuDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Shouzhen ChenDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Rongyang LiDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, China.
Benkang ShiDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Yaofeng ZhuDepartment of Urology, Qilu Hospital of Shandong University, Jinan, China.
Qilu Hospital of Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: With the widespread adoption of prostatic-specific antigen (PSA) screening, the detection rates of prostate cancer (PCa) have increased. Due to the low specificity and high false-positive rate of serum PSA levels, it was difficult to diagnose PCa accurately. To improve the diagnosis of PCa and clinically significant prostate cancer (CSPCa), we established novel models on the basis of the prostate health index (PHI) and multiparametric magnetic resonance imaging (mpMRI) in the Asian population. Methods: We retrospectively collected the clinical indicators of patients with TPSA at 4-20 ng/ml. Furthermore, mpMRI was performed using a 3.0-T scanner and reported in the Prostate Imaging Reporting and Data System version 2.1 (PI-RADS). Univariable and multivariable logistic analyses were performed to construct the models. The performance of different models based on PSA derivatives, PHI derivatives, PI-RADS, and a combination of PHI derivatives and PI-RADS was evaluated. Results: Among the 128 patients, 47 (36.72%) patients were diagnosed with CSPCa and 81 (63.28%) patients were diagnosed with non-CSPCa. Of the 81 (63.28%) patients, 8 (6.25%) patients were diagnosed with Gleason Grade 1 PCa and 73 (57.03%) patients were diagnosed with non-PCa. In the analysis of the receiver operator characteristic (ROC) curves in TPSA 4-20 ng/ml, the multivariable model for PCa was significantly larger than that for the model based on the PI-RADS ( Conclusions: The models combining PHI derivatives and PI-RADS performed better in detecting PCa and CSPCa than the models based on either PHI or PI-RADS.

Indexed as

diagnosismodelsmultiparametric magnetic resonance imagingprostate cancerprostate health index

Identifiers

PMID35903679
PMCPMC9316170
OpenAlexW4285088889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.